Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The changing environment for US pharmaceuticals.

P R Meyer1

  • 1US Pharmaceuticals Group, Pfizer Inc, New York, USA.

Pharmacoeconomics
|December 9, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of internal fixation device support in experimentally produced fractures of the dorsolumbar spine.

Orthopedics·2014
Same author

Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates.

Antimicrobial agents and chemotherapy·2000
Same author

Emergency, acute, and surgical management of spine trauma.

Archives of physical medicine and rehabilitation·1999
Same author

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

Molecular cell·1999
Same author

Management of an unstable lumbar fracture with a laminar split.

Spinal cord·1999
Same author

Diffuse idiopathic skeletal hyperostosis in the cervical spine.

Clinical orthopaedics and related research·1999
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
See all related articles

US health reform may impact pharmaceutical research through potential price controls. Policymakers must consider the evolving pharmaceutical market to avoid hindering drug innovation.

Area of Science:

  • Health Policy
  • Pharmaceutical Economics
  • Drug Development

Background:

  • US health reform is a major policy focus with significant implications for the pharmaceutical industry.
  • The pharmaceutical market is undergoing substantial changes, including reduced price increases and increased discounting.
  • The growth of managed care influences pharmaceutical pricing and market dynamics.

Purpose of the Study:

  • To analyze the potential impact of health reform on pharmaceutical research incentives.
  • To highlight the evolving pharmaceutical marketplace and its relevance to policy decisions.

Main Methods:

  • Qualitative analysis of current trends in the pharmaceutical market.
  • Review of policy implications for pharmaceutical research and development.

Related Experiment Videos

Main Results:

  • Pharmaceutical market changes include decreased price hikes, increased discounting, and lower launch prices for new drugs.
  • The industry faces challenges such as job reductions and declining market valuations.
  • Potential price controls from health reform could negatively affect pharmaceutical research incentives.

Conclusions:

  • Policymakers must consider the current pharmaceutical market conditions when formulating health reform.
  • Failure to account for market realities could create additional barriers for the industry.
  • Compromising incentives for pharmaceutical research could have long-term consequences for drug innovation.